New combo therapy aims to slow lung scarring
NCT ID NCT07570888
First seen May 08, 2026 · Last updated May 08, 2026
Summary
This study tests adding nerandomilast to the standard drug mycophenolate for people with pulmonary fibrosis (lung scarring). About 120 adults will take the combination for 4 months. The main goal is to see if most patients can stay on the treatment without stopping. Researchers will also check side effects and measure lung function changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE (ILD) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.